Peritoneal Carcinomatosis of Colorectal Origin

Koppe, Manuel J.; Boerman, Otto C.; Oyen, Wim J.G.; Bleichrodt, Robert P.

doi:10.1097/01.sla.0000197702.46394.16

Cited by 437 publications

(127 citation statements)

References 77 publications

Supporting

Mentioning

126

Contrasting

Unclassified

Order By: Relevance

“…It is supposed to develop metachronously in 4-19% of patients, 24 but the reported incidence at autopsy ranges between 40 and 80%. 25,26 The molecular signals generated in the peritoneal cavity, and specifically the ability to attract supportive macrophages at serosal sites, might play a role in the ability of neoplastic cells to yield peritoneal lesions and in their kinetics.…”

Section: Discussionmentioning

confidence: 99%

Leukocytes recruited by tumor-derived HMGB1 sustain peritoneal carcinomatosis

et al. 2016

View full text Add to dashboard Cite

The factors that determine whether disseminated transformed cells in vivo yield neoplastic lesions have only been partially identified. We established an ad hoc model of peritoneal carcinomatosis by injecting colon carcinoma cells in mice. Tumor cells recruit inflammatory leukocytes, mostly macrophages, and generate neoplastic peritoneal lesions. Phagocyte depletion via clodronate treatment reduces neoplastic growth. Colon carcinoma cells release a prototypic damage-associated molecular pattern (DAMP)/alarmin, High Mobility Group Box1 (HMGB1), which attracts leukocytes. Exogenous HMGB1 accelerates leukocyte recruitment, macrophage infiltration, tumor growth and vascularization. Lentiviral-based HMGB1 knockdown or pharmacological interference with its extracellular impair macrophage recruitment and tumor growth. Our findings provide a preclinical proof of principle that strategies based on preventing HMGB1-driven recruitment of leukocytes could be used for treating peritoneal carcinomatosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Leukocytes recruited by tumor-derived HMGB1 sustain peritoneal carcinomatosis

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Colorectal cancer with peritoneal carcinomatosis was considered an incurable disease three decades ago and these patients usually died because of intestinal obstruction [8,9]. The last two decades aggressive cytoreductive surgery in combination with intraperitoneal chemotherapy has demonstrated improved results in properly selected patients [10][11][12].…”

Section: Discussionmentioning

confidence: 99%

Peritoneal Colorectal Carcinomatosis Treated with Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy

Tentes¹,

Korakianitis²,

Pallas³

et al. 2012

View full text Add to dashboard Cite

Background-Aims: Peritoneal colorectal carcinomatosis is a potentially curative disease. The purpose of the study is the retrospective analysis of survival of the patients with peritoneal colorectal carcinomatosis that underwent cytoreductive surgery and perioperative intraperitoneal chemotherapy and the identification of prognostic variables of the disease. Patients-Methods: Patients with primary or recurrent colorectal cancer and peritoneal carcinomatosis were included in the study. Clinical variables were correlated to survival, recurrence, hospital mortality, and morbidity. Results: From 2000-2010, 28 patients underwent 33 cytoreductive operations. The hospital mortality and morbidity rate was 9.1% and 45.5% respectively. The overall 5-year and median survival time was 29.2% and 19 months respectively. The extent of peritoneal carcinomatosis (p = 0.0003) and the completeness of cytoreduction (p = 0.0002) were related to survival. The completeness of cytoreduction (p = 0.003) was the single prognostic variable of survival. The recurrence rate was 42.4% and the use of systemic chemotherapy was identified as the single prognostic variable of recurrence (p = 0.047). Conclusions:Patients with limited extent of peritoneal colorectal carcinomatosis who undergo complete cytoreduction may be offered long-term survival.

show abstract

“…Moreover, earlier reports on HIPEC suffered from the very small number of included patients, making any stratification impossible. However, beside their role as independent prognostic factors, tumor characteristics are mandatory to get a better stratification, given that the only outcome parameter used is the overall survival, whereas only few studies considered quality of life and PC-free survival [160][161][162] .…”

Section: Peritoneal Carcinomatosis From Colo-rectal Cancermentioning

confidence: 99%

Peritoneal Carcinomatosis

2011

Encyclopedia of Cancer

View full text Add to dashboard Cite

Several gastrointestinal and gynecological malignancies have the potential to disseminate and grow in the peritoneal cavity. The occurrence of peritoneal carcinomatosis (PC) has been shown to significantly decrease overall survival in patients with liver and/or extraperitoneal metastases from gastrointestinal cancer. During the last three decades, the understanding of the biology and pathways of dissemination of tumors with intraperitoneal spread, and the understanding of the protective function of the peritoneal barrier against tumoral seeding, has prompted the concept that PC is a loco-regional disease: in absence of other systemic metastases, multimodal approaches combining aggressive cytoreductive surgery, intraperitoneal hyperthermic chemotherapy and systemic chemotherapy have been proposed and are actually considered promising methods to improve loco-regional control of the disease, and ultimately to increase survival. The aim of this review article is to present the evidence on treatment of PC in different tumors, in order to provide patients with a proper surgical and multidisciplinary treatment focused on optimal control of their locoregional disease.© 2013 Baishideng Publishing Group Co., Limited. All rights reserved.Key words: Carcinosis; Peritoneal; Ovarian; Gastric; Colorectal; Hipec; Intraperitoneal chemotherapy; Cytoreductive surgery; Cancer; Advanced Core tip: This review aims to present the evidence on treatment of peritoneal carcinosis in different tumors, in order to provide patients with a proper surgical and multidisciplinary treatment focused on optimal control of their locoregional disease.

show abstract

Peritoneal Carcinomatosis of Colorectal Origin

Cited by 437 publications

References 77 publications

Leukocytes recruited by tumor-derived HMGB1 sustain peritoneal carcinomatosis

Leukocytes recruited by tumor-derived HMGB1 sustain peritoneal carcinomatosis

Peritoneal Colorectal Carcinomatosis Treated with Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy

Peritoneal Carcinomatosis

Contact Info

Product

Resources

About